Thalitone

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thalitone

Property Description
Active Ingredient Chlorthalidone (INN)
Form Oral Tablet
Pharmacological Class Thiazide-Like Diuretic; Antihypertensive Agent
General Purpose Regulating fluid balance and lowering blood pressure
Origin Synthetic, Sulfonamide-Derived Drug

What Type of Medicine is Thalitone?

The medicine known by the brand name Thalitone is a prescription-only medication with the active ingredient chlorthalidone, which is chemically classified as a thiazide-like diuretic and a systemic antihypertensive agent. It is a sulfonamide-derived drug used to manage conditions related to fluid and pressure imbalance. While often clinically grouped with traditional thiazides, chlorthalidone is structurally distinct, possessing a significantly prolonged action and extended half-life. This distinct kinetic profile is a differentiating factor, allowing for sustained control of the circulatory system’s hydrostatic pressure.


Composition and Form: What is Chlorthalidone Made Of?

Chlorthalidone is a synthetic compound supplied for oral consumption in the form of a tablet, representing its standard dosage form and route of administration. The composition consists solely of the active ingredient, chlorthalidone, alongside non-active solid excipients—such as microcrystalline cellulose and magnesium stearate—necessary for creating the physical tablet vehicle. This compound has an established, evidence-based role in long-term cardiovascular management. The drug may be prescribed as a single-ingredient product or in a fixed-dose combination tablet.


General Purpose: What Does Thalitone Help Achieve?

The general purpose of this medicine is to promote overall cardiovascular health by regulating the body's fluid and electrolyte balance. It achieves this by encouraging the kidneys to excrete more sodium and chloride ions, which increases urine output, or diuresis, and effectively reduces the total fluid volume in the body. This action helps to manage two primary physiological concerns: lowering elevated blood pressure and relieving generalized fluid accumulation (edema). A typical scenario involves using the drug to help maintain consistent pressure levels in adults.

Regulatory References

  1. MedlinePlus: Chlorthalidone Drug Information
  2. Chlorthalidone - StatPearls - NCBI Bookshelf

What side effects are possible with Thalitone?

Possible Side Effects and Safety Information

The official safety profile for chlorthalidone (Thalitone), a sulfonamide-derived drug, is heavily structured by its impact on metabolism and electrolyte balance, as documented in government regulatory sources. The most frequently observed adverse reactions are classified as Very Common (ge10%), primarily involving hypokalemia (low potassium), hyperuricemia (high uric acid), and hyperlipidemia (high cholesterol/lipids).

Other adverse effects are grouped by System-Organ Class (SOC) and frequency. Reactions classified as Common (ge1% to <10%) include postural hypotension (low blood pressure upon standing), dizziness, hyponatremia (low sodium), hyperglycemia, and skin reactions such as rash or urticaria. Postural hypotension is noted to be more common when treatment is initiated.

Serious and Population-Specific Safety Notes

The regulatory label documents several Rare to Very Rare serious adverse reactions. These include severe hematological disorders such as aplastic anemia and agranulocytosis, severe skin reactions like Toxic Epidermal Necrolysis (TEN), and acute ocular issues such as Acute Angle-Closure Glaucoma.

Official safety constraints explicitly note that the drug is contraindicated in conditions such as anuria (inability to urinate), known hypersensitivity to sulfonamide derivatives, and severe renal or hepatic impairment. Specific safety considerations are required for older adults due to increased susceptibility to hyponatremia and for patients with impaired hepatic function, where minor fluid changes could precipitate hepatic coma.

Overdose and Emergency Response

If you suspect an overdose of Thalitone (chlorthalidone), you should immediately seek emergency medical attention.

When to Seek Immediate Medical Help

Call your local emergency number (such as 911 in the U.S.) or contact a poison control center right away if you believe an overdose has occurred. Do not wait for symptoms to worsen. If the person has collapsed, is having a seizure, has severe breathing difficulty, or cannot be awakened, call emergency services immediately.

Potential Overdose Manifestations

Acute overdosage of chlorthalidone is typically associated with pronounced physical signs due to the drug’s effects on fluid balance. Documented symptoms of acute overdose generally involve:

  • Gastrointestinal Distress: Nausea.
  • Neurological Signs: Dizziness and general weakness.
  • Systemic Disturbances: Severe changes in the body’s electrolyte balance (such as low sodium or low potassium), which can present as extreme thirst, confusion, muscle cramps, or a very fast or irregular heartbeat. Hypotension, or abnormally low blood pressure, may also occur, which can lead to light-headedness or fainting.

There is no specific antidote for a chlorthalidone overdose. Emergency management involves providing supportive treatment, such as correcting fluid and electrolyte imbalances in a supervised setting. Bringing the medication container to the hospital can assist medical professionals. This information should not be used in place of emergency professional guidance.

Therapeutic Uses of Thalitone

What Thalitone Treats: Main Uses and Benefits

Thalitone (chlorthalidone) is commonly used to help with managing conditions characterized by systemic or localized discomfort, such as chronic high blood pressure and fluid retention.

This medicine is considered relevant for easing symptom clusters that may become intense or disruptive in conditions such as essential hypertension, congestive heart failure, and certain fluid retention patterns linked to advanced liver or kidney disease. For patients with these chronic illnesses, Thalitone generally supports the handling of distressing manifestations related to persistently elevated systemic pressure and systemic fluid overload (edema).

“This application helps support general well-being during symptomatic phases by contributing to the management of risk factors for major cardiovascular events.”

This drug may also assist with managing recurrent manifestations that interfere with daily comfort, such as the symptomatic pattern of calcium kidney stones in specific metabolic contexts. The primary therapeutic focus is on symptom management across conditions associated with acute or disruptive episodes.


Quick Fact: Symptom Management
Thalitone is applied across therapeutic domains where additional symptomatic support is needed for chronically high systemic pressure and the generalized accumulation of excess fluid, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Thalitone (Chlorthalidone)

Official regulatory labeling defines specific populations who must not use Thalitone and others who require special caution. This information is based on documented risks and efficacy data.

Classification Who Cannot Use Thalitone (Contraindications)
Absolute Prohibition Patients with anuria (inability to produce urine).
Patients with known hypersensitivity to chlorthalidone or sulfonamide-derived drugs.
Classification Who Requires Restricted/Conditional Use
Organ Function Use with caution in severe renal disease or impaired hepatic function, as it may precipitate azotemia or hepatic coma.
Metabolic Pre-conditions Patients with pre-existing electrolyte imbalance (e.g., severe hypokalemia) or a history of gout/hyperuricemia must be carefully monitored.
Pediatric Use Safety and effectiveness have not been established in the pediatric population.
Pregnancy/Lactation Routine use during pregnancy is considered inappropriate. It is generally not recommended for women who are breastfeeding as the drug is excreted in breast milk and may suppress lactation.

Eligibility is limited to adult patients without these specific contraindications or conditions that necessitate close medical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for chlorthalidone (Thalitone) as found in government regulatory labeling. The combination of chlorthalidone with the medical condition Anuria (absence of urine formation) is formally listed as a contraindication.


Interaction Type Interacting Substances/Categories Regulatory Outcome
Exposure-Altering Lithium Reduces lithium's renal clearance, increasing the risk of lithium toxicity.
Pharmacodynamic Other Antihypertensive Drugs May add to or potentiate the blood pressure-lowering action.
Corticosteroids or ACTH Increased risk of hypokalemia (low potassium) due to additive electrolyte effects.
NSAIDs Can reduce the diuretic and antihypertensive effect of chlorthalidone.
Endocrine Antidiabetic Agents Dosage requirements for insulin and oral agents may be altered (increased, decreased, or unchanged).
Substance/Alcohol Alcohol Ingestion of alcohol can officially aggravate orthostatic hypotension.

Population- and Condition-Specific Interaction Notes

For patients with Impaired Hepatic Function or Progressive Liver Disease, minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Additionally, chlorthalidone may increase the responsiveness to the skeletal muscle relaxant Tubocurarine and decrease arterial responsiveness to Norepinephrine.

Mechanism of Action

How Thalitone Works

Thalitone (chlorthalidone) modulates fluid balance and vascular tone by engaging specific molecular targets, leading to specific physiological consequences.


Inhibition of Renal Ion Transport

The primary action begins in the kidney's Distal Convoluted Tubule (DCT), where chlorthalidone acts as a competitive inhibitor of the Sodium-Chloride Symporter (NCC). Blocking this transporter prevents the reabsorption of sodium ( Na^+) and chloride ( Cl^-) ions back into the blood. The retained ions exert an osmotic pull that restricts water reabsorption, initiating increased urinary output and a reduction in overall plasma and extracellular fluid volume (ECFV).


Chronic Modulation of Vascular Resistance

Independent of volume changes, the drug exerts a long-term, direct effect on the peripheral vasculature. By altering ion flux within the vessel wall smooth muscle, it modifies the intracellular handling of calcium ions, promoting muscle relaxation. This mechanism results in a sustained decrease in Systemic Vascular Resistance (SVR), influencing the hydrostatic pressure exerted on the artery walls.


️ Secondary Electrolyte Cascade Effects

Inhibition of the NCC inherently influences downstream ion exchange mechanisms. The resulting increased delivery of Na^+ to the collecting duct enhances Na^+/ K^+ exchange, causing increased excretion of potassium ( K^+) and magnesium ( Mg^2+). Conversely, the mechanism promotes the reabsorption of calcium ( Ca^2+) in the DCT, leading to reduced urinary calcium loss.

Dosage and Administration Information

Thalitone (chlorthalidone) is administered as an oral tablet in a standardized, long-term protocol. The medication is taken as a single dose once daily, with instructions directing intake in the morning and with food. Therapy is consistently initiated at the lowest effective dose and subsequently adjusted, or titrated, based on the individual's response.

Usage is defined by specific, high-level dose ranges for the two main applications:

Application Initial Dosing Range Maximum Daily Dose (General)
Hypertension 15 mg to 25 mg once daily. 100 mg (generic)
Edema 50 mg to 100 mg daily, or 100 mg alternate days. 200 mg

Population-Specific Use Principles

Dosing is modified by population constraints. For older adults, dose selection requires caution and typically starts at the lower end of the established range. For individuals with severe renal impairment, the drug is considered ineffective and should not be used if creatinine clearance is below 10 mL/min. If a single dose is missed, standard practice suggests skipping the missed dose if it is almost time for the next scheduled dose, rather than attempting to take a double dose. This structure establishes a clear, procedural framework for the drug's administration and adjustment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Thalitone


Evidence for Use in Managing High Blood Pressure (Hypertension)

Chlorthalidone's use for primary high blood pressure was evaluated in extensive Randomized Controlled Trials (RCTs) (e.g., ALLHAT, SHEP) over many years of observation. These studies observed treatment regimens in adults and older adults, including those with additional cardiovascular risk factors. Research reported patterns of blood pressure changes and tracked the incidence of major cardiovascular events, such as heart failure and stroke, when observing the chlorthalidone regimen compared to specific other regimens or placebo. However, some trials exploring specific comparative regimens reported data showing patterns without measurable distinction in the overall primary outcome.


Evidence for Use in Addressing Excess Fluid Accumulation (Edema)

The research record for managing generalized excess fluid accumulation (edema) includes evidence supported by regulatory review and secondary analyses of major cardiovascular trials. These analyses show that long-term use in hypertensive patients was associated with observed patterns of lower heart failure event incidence. The findings contribute to understanding how this medicine was studied for systemic fluid imbalance in certain conditions.


Evidence for Use in High-Risk Kidney Populations

Dedicated, short-term Randomized Controlled Trials were conducted in a high-risk population: adults with uncontrolled high blood pressure and advanced Chronic Kidney Disease (CKD) Stage 4. This research explored short-term changes, and findings indicated measured differences in 24-hour blood pressure readings compared to the placebo group after a 12-week period. Data indicated patterns related to measured physiological markers were observed during the study period.


Long-Term Studies and What is Still Uncertain About the Research

Long-term research on hypertension focused on follow-up durations up to several years to view extended outcomes and durability. However, long-term effects are not fully established across all indications, particularly for the Advanced CKD population due to limited trial duration. Comparative evidence is lacking in specific areas, such as the direct observation alongside all other diuretics for non-cardiac fluid management. Furthermore, regulatory summaries indicate that some subgroup findings are uncertain, meaning observed patterns may vary across different patient characteristics.

Frequently Asked Questions (FAQ)

Common questions about Thalitone (FAQ)

Q: How quickly does Thalitone start to lower blood pressure?

A: Regulatory information indicates that the diuretic effect, which increases urine output, begins within a few hours of taking a dose. However, it may take some time before an overall change in blood pressure or a noticeable reduction in fluid-related swelling is observed.

Q: Can I stop taking Thalitone if my blood pressure returns to normal?

A: For managing high blood pressure, this medication is typically part of a long-term treatment plan meant to help control the condition, not cure it. Regulatory guidance suggests that discontinuing the drug should be discussed with a healthcare provider.

Q: Does Thalitone interact with common pain relievers like ibuprofen?

A: Yes, official drug labeling notes an interaction with non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen. Taking this medicine alongside NSAIDs may reduce its ability to lower blood pressure and decrease fluid retention.

Q: Do people with diabetes have special considerations for using Thalitone?

A: Official warnings note that this medicine can cause an increase in blood sugar levels (hyperglycemia). Official documents state that the dosage requirements for antidiabetic agents may be altered, and patient monitoring is a necessary consideration.

Q: Is Thalitone safe for use in older adults?

A: Regulatory sources advise that dose selection for older adults requires caution and should typically start at the lower end of the established range. This is because older adults may be more sensitive to the drug’s effects, particularly concerning changes in kidney function.

Q: Can women who are pregnant or breastfeeding use Thalitone?

A: Official documents state that routine use during pregnancy is considered inappropriate. Use during breastfeeding is generally not recommended because the drug is excreted in human milk and may suppress lactation or pose a risk of adverse effects in the nursing infant.

Q: Do I need regular blood tests while I am taking Thalitone?

A: Yes, periodic monitoring of serum electrolytes is generally recommended while taking this medicine. This is because it can cause shifts in the body's mineral balance, such as low potassium (hypokalemia) and low sodium (hyponatremia).

Q: Does Thalitone interact with supplements like magnesium or calcium?

A: The drug's mechanism naturally influences the balance of these electrolytes. Specifically, it can lead to increased urinary loss of magnesium and reduced urinary loss of calcium. Due to this mechanism, monitoring of these electrolyte levels may be part of the therapeutic plan.

Q: Can I take Thalitone if I am lactose intolerant?

A: According to the official product information, the tablet formulation includes anhydrous lactose as an inactive ingredient (excipient). Official labeling identifies this component, and patients with intolerance are advised to review the inactive ingredients.

Q: Can Thalitone be used for conditions other than high blood pressure or swelling?

A: Official indications also include its use as adjunctive therapy for swelling (edema) that is associated with hepatic cirrhosis or fluid retention related to corticosteroid and estrogen therapy.

Q: What are the most common side effects reported by people taking Thalitone?

A: The most frequently reported adverse reactions include shifts in electrolyte levels, such as low potassium and low sodium. Other common effects include high uric acid (hyperuricemia), high lipids (hyperlipidemia), dizziness, and low blood pressure upon standing (postural hypotension).

Q: Does Thalitone cause weight gain or weight loss?

A: As a diuretic, this medicine may cause temporary weight loss that is related to the removal of excess fluid from the body. The effect is related to fluid removal. Official information does not cite direct influence on body fat or weight gain as a common or very common adverse reaction.

Q: Is it normal to feel dizzy or lightheaded when first starting Thalitone?

A: Dizziness and low blood pressure upon standing (postural hypotension) are common side effects listed in official documents. Postural hypotension is specifically noted to be more common when treatment with the medicine is first initiated.

Q: Are there any specific foods or drinks I should avoid while on Thalitone?

A: Official labeling advises that ingesting alcohol can potentially worsen orthostatic hypotension (low blood pressure when standing up). Beyond alcohol, official drug interaction listings do not require the avoidance of specific foods.

Q: Are there restrictions on using Thalitone for people with kidney problems?

A: Yes, the drug is formally contraindicated (should not be used) in patients who have anuria, which is the inability to produce urine. It should also be used with caution in severe renal (kidney) disease, as it may increase the risk of worsening kidney function.

Q: Does Thalitone make you tired or affect energy levels?

A: Unusual tiredness or weakness is listed as a potential adverse effect associated with this medication. This feeling is sometimes related to the changes in electrolyte balance that the drug can cause.

Q: What is the maximum amount of time someone is expected to take Thalitone?

A: The medication is often prescribed as part of long-term treatment protocols for high blood pressure. Major clinical trials supporting its use have observed patient regimens over periods of several years.

Q: What research evidence supports the use of Thalitone for lowering blood pressure?

A: The use of the active ingredient for lowering blood pressure is supported by extensive evidence from controlled clinical trials. These studies demonstrated that the reduction in blood pressure achieved through this medication helps to reduce the overall risk of major cardiovascular events, such as stroke and heart attack.

Q: Are there studies on the long-term effects of taking Thalitone?

A: Yes, long-term research on the use of chlorthalidone for hypertension has involved follow-up periods extending up to several years to evaluate extended outcomes. However, regulatory summaries note that long-term effects across all potential indications are not fully established.

Q: Is the effect of Thalitone permanent, or does it stop when I stop taking it?

A: The medicine is primarily used for the control of chronic conditions like high blood pressure, and its therapeutic effects stop when treatment is discontinued. If the medication is discontinued, the effects stop, and the treated condition may return, which is why stopping should be discussed with a healthcare professional.

Q: Does Thalitone have any known effect on liver function?

A: Regulatory warnings state the drug must be used with caution in patients with impaired hepatic (liver) function or progressive liver disease. In these cases, minor fluid changes caused by the drug may increase the risk of precipitating hepatic coma. General liver toxicity is not listed as a common adverse reaction.

Q: What should I do if my blood pressure doesn't improve while taking Thalitone?

A: Official documentation for this medication indicates that the dose is adjusted, or titrated, based on the individual's response to the treatment. Lack of improvement is generally a sign that therapeutic adjustment is needed, which is determined by the prescriber.

Q: Is there a risk of dehydration while using Thalitone?

A: Yes, as a diuretic (water pill), the drug increases the body's output of urine. Monitoring for signs of dehydration and maintaining fluid balance are typically part of the treatment management plan.

Q: Does Thalitone cause muscle cramps?

A: Muscle cramps or muscle pain are listed in official documents as potential signs of low potassium (hypokalemia). Low potassium is a very common adverse reaction associated with the use of this medicine.

How should Thalitone be stored and disposed of?

Official Storage and Disposal Requirements for Thalitone

Thalitone (chlorthalidone) must be stored according to specific regulatory requirements to maintain its stability and effectiveness. The medication should be kept at controlled room temperature, ideally between 20 C and 25 C (68 F and 77 F). Protect the tablets from excessive heat, freezing, moisture, and direct light.

Keep the medicine in its original container with the lid tightly closed.

Child Safety: Always store Thalitone out of the reach of children.

Disposal: Do not dispose of unused or expired Thalitone by flushing it down a toilet or pouring it down a drain. Use an official drug take-back program or consult your pharmacist for proper disposal methods that comply with local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thalitone found in:

A-Z Index: